The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Surprised amp isn’t a lot lower. They are in such a mess.
Somebody. Maybe meek himself deleted the posts. I think he felt stupid after thinking he has got in here cheap. Didn’t realise how up the creek amp is.
Amp owe well over £20million.
No even at 70p. Amp are in negative territory
Lol. Amp was only at 1.8. Because people were expecting motif to go over £1. Pmsl. Gilo. For an analyst and lawyer. Lol.
Lol. Motif needs to ten bag from here just to break even for AMP
The call will be held to discuss recent events that Motif has announced and the Company's plans. No new material information will be disclosed during the call. Lol. It’s material information we are waiting for.
Vancomycin is generic now. Dozens are making it
If you believe in Iclaprim you should buy Motif. Motif needs to 10 bag before amp is in positive teritory
Only 300k now. Just letting them ride. This has already moved up for no reason, it could go even further
Its been passed around from company to company for around 10 years now.
According to Motif Bio, iclaprim has an underutilised mechanism of action compared to other antibiotics. The diaminopyrimidine dihydrofolate reductase blocker, was licenced in 2001 from Roche by its spin-out company Arpida, which later merged with Evolva. Arpida ran two Phase III clinical trials for complicated skin and skin structure infections, called ASSIST 1 and 2, that were completed by 2008 but as of 2017 had not been published in the medical literature.
A NDA was filed with the FDA based on these trials and was rejected due to failure to show non-inferiority and due to safety concerns, especially drug-induced QT prolongation. The FDA advisory committee said that the drug "should not be developed further" based on the results presented. A parallel application for marketing approval to the EMA was withdrawn in 2009; in the announcement of the withdrawal, the EMA said that there was insufficient data from clinical studies to justify the dosage proposed by the company and that resistance to the drug had already been seen in the clinical trial data.
Arpida sold off iclaprim to Acino Pharma in November 2009 and the company handed over the rights to to a group called Life Sciences Management Group, Inc., which assigned its rigths to Nuprim. In 2015 Motif BioSciences Inc. and Nuprim merged. In 2017, Motif Bio announced positive results with iclaprim in two Phase III trials (called REVIVE 1 and 2) to show non-inferiority to vancomycin in acute skin and skin structure infection. In September 2017 the FDA granted orphan drug status to iclaprim for the treatment of Staphylococcus aureus lung infections in people with cystic fibrosis.
"should not be developed further" based on the results presented --------that put the last lot off I suppose.
Do you know the full history of Iclaprim meek ?
At 31 December 2018, the Company had cash of $12.3 million and $15 million of debt drawn from its Hercules loan facility. The Company is financed into the second quarter of 2019 but will need to raise capital in the near term.
I wouldn’t be buying any more anytime soon. Not sure why people are still buying
What price did you buy in at. Don’t forget to bank profits.
Meek. If I wanted a better buy in I could buy in now at .48. But it’s nowhere near as attractive as it was when the news was due. Could still get good news from Motif.
I bought in just over 1 and sold vast majority in the 1.8s. Bought into Motif just under 6 and sold at 11. Bought back into motif this morning and sold a couple of hours later for 20%. I bought amp on the hope of a leveraged holding in Motif. That was based on motif moving from the then 40p to 120p or more. At which point amp would be starting to use its leverage. Obviously the deal hasn’t gone through. There is still hope. Even if motif were to ten bag at this price. Amp is still in negative territory
Meek. I see you’ve bought in on Twitter ramps. Just don’t be left holding it. Bank profits. I’ve made a decent amount ( could have made more as I sold too early both times ) these shares are rising without substance. Motif needs to reach over £1 before iAmp will be moving into positive territory.